Drugs / MK-8666
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01971554 | Oct 2013 → Apr 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8666 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01971554 ↗ |
| Action | Activate | “a partial GPR40 agonist” PMID 28727908 ↗ Jul 2017 |
| Modality | Small molecule | — CHEMBL4297471 ↗ |
| Route | Oral | “MK-8666, capsules, oral, QD, Days 1 to 14” NCT01971554 ↗ |